For example, Cao et al. [14] applied network pharmacology and demonstrated that the active components of Yinqiaosan, that is, luteolin, naringenin, and farnesin, can act on multiple targets, such as tumor necrosis factor (TNF), mitogen-activated protein kinase 1 (MAPK1), and Caspase-3 (CASP3), to regulate signaling pathways, such as Kaposi sarcoma-associated herpesvirus infection, advanced glycation end products (AGE), and their receptors, thereby curing COVID-19. This evidence concerns the gene MAPK1 and COVID-19.